Seth J. Baum
Impact in
-
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diet, Metabolism, and Disease
- Diabetes Treatment and Management
- Surgery top 0.5%
- Lipoproteins and Cardiovascular Health
Papers in
- Surgery 61
- Lipoproteins and Cardiovascular Health 55
-
- Lipid metabolism and disorders 18
- Co-authors
- Erik S.G. Stroes (4 shared papers)Daniel Gaudet (20 shared papers)Patrick M. Moriarty (8 shared papers)Joseph Lee Witztum (6 shared papers)Ewa Karwatowska‐Prokopczuk (8 shared papers)Louis St L O'Dea (4 shared papers)Sotirios Tsimikas (7 shared papers)Michael David Shapiro (8 shared papers)
- Journals
- Journal of clinical lipidology (22 papers)Journal of the European Academy of Dermatology and Venereology (12 papers)Journal of the American College of Cardiology (10 papers)European Heart Journal (6 papers)JAMA Cardiology (5 papers)
- Partner nations
- United StatesIsraelCanada
In The Last Decade
Seth J. Baum
125 papers receiving 8.2k citations
Seth J. Baum's Hit Papers
Peers
Comparison fields: 5 of 132
- Endocrinology, Diabetes and Metabolism 1.9k
- Surgery 3.5k
- Cardiology and Cardiovascular Medicine 1.7k
- Epidemiology 1.7k
- Cancer Research 744
Countries citing papers authored by Seth J. Baum
This map shows the geographic impact of Seth J. Baum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seth J. Baum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seth J. Baum more than expected).
Fields of papers citing papers by Seth J. Baum
This network shows the impact of papers produced by Seth J. Baum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seth J. Baum. The network helps show where Seth J. Baum may publish in the future.
Co-authors
The 25 scholars most cited alongside Seth J. Baum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 133 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Hit paper breakdown → | 2024 | 1267 |
| 2 | Lipoprotein(a) Reduction in Persons with Cardiovascular Disease Hit paper breakdown → | 2020 | 789 |
| 3 | Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Hit paper breakdown → | 2019 | 638 |
| 4 | Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Hit paper breakdown → | 2024 | 526 |
| 5 | Clinical Genetic Testing for Familial Hypercholesterolemia Hit paper breakdown → | 2018 | 460 |
| 6 | Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease Hit paper breakdown → | 2022 | 421 |
| 7 | Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease Hit paper breakdown → | 2019 | 373 |
| 8 | 2016 | 328 | |
| 9 | Evinacumab in Patients with Refractory Hypercholesterolemia Hit paper breakdown → | 2020 | 246 |
| 10 | Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia Hit paper breakdown → | 2020 | 229 |
| 11 | 2012 | 223 | |
| 12 | Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a) Hit paper breakdown → | 2022 | 196 |
| 13 | Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2021 | 189 |
| 14 | 2016 | 185 | |
| 15 | Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US Hit paper breakdown → | 2021 | 180 |
| 16 | Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk Hit paper breakdown → | 2021 | 167 |
| 17 | 2021 | 121 | |
| 18 | 2023 | 108 | |
| 19 | Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Hit paper breakdown → | 2024 | 83 |
| 20 | 2009 | 79 |
About Seth J. Baum
Seth J. Baum is a scholar working on Surgery, Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Cancer Research and Pathology and Forensic Medicine, having authored 133 papers that have together received 8.5k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (55 papers), Lipid metabolism and disorders (18 papers), Cancer, Lipids, and Metabolism (12 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers), Autoimmune Bullous Skin Diseases (10 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers), Pharmaceutical Economics and Policy (8 papers) and Liver Disease Diagnosis and Treatment (8 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.9k citations), Surgery (3.5k citations), Cardiology and Cardiovascular Medicine (1.7k citations), Epidemiology (1.7k citations) and Cancer Research (744 citations). Seth J. Baum has collaborated with scholars based in United States, Israel and Canada. Frequent co-authors include Erik S.G. Stroes, Daniel Gaudet, Patrick M. Moriarty, Joseph Lee Witztum, Ewa Karwatowska‐Prokopczuk, Louis St L O'Dea, Sotirios Tsimikas, Michael David Shapiro, Jean‐Claude Tardif and Robert S. Rosenson. Their work appears in journals such as Journal of clinical lipidology, Journal of the European Academy of Dermatology and Venereology, Journal of the American College of Cardiology, European Heart Journal and JAMA Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.